{"id":"W2396153198","doi":"10.1200/jco.2006.24.18_suppl.4631","title":"Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP)","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; BC Cancer Agency","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Neutropenia; Prostate cancer; Febrile neutropenia; Internal medicine; Clinical endpoint; Adverse effect; Nausea; Phases of clinical research; Oncology; Chemotherapy; Urology; Surgery; Gastroenterology; Cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001858097,0.001573381,0.002275871,0.000424599,0.000677663,0.0008732042,0.001223033,0.001083401,0.004507819],"category_scores_gemma":[0.0009667045,0.0008280192,0.0009388921,0.000572003,0.001384962,0.0005500031,0.0003703164,0.003092699,0.0008788971],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00259813,"about_ca_system_score_gemma":0.008429307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01999046,"about_ca_topic_score_gemma":0.05932325,"domain_scores_codex":[0.999433,0.0002280925,0.00002288784,0.00009409526,0.00006958167,0.0001523089],"domain_scores_gemma":[0.9988153,0.0001335424,0.0001461862,0.00008900325,0.00007564652,0.0007403041],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7773985,0.1254817,0.006324347,0.000533387,0.0006924444,0.0002370076,0.0004613668,0.002494132,0.02800792,0.0001912665,0.003560537,0.05461736],"study_design_scores_gemma":[0.469435,0.5127223,0.01231178,0.00002569773,0.0002158342,0.0001531871,0.00006553952,0.0007814777,0.00201011,0.00008841927,0.002164338,0.00002634168],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910421,0.0007628737,0.0003674334,0.0002584465,0.00008565555,0.005152579,0.0008292813,0.00007767769,0.001423874],"genre_scores_gemma":[0.9846091,0.001224734,0.002719177,0.000686726,0.0001452942,0.004611243,0.002519442,0.00002790627,0.003456362],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01999046,"threshold_uncertainty_score":0.03974825,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08346536495370124,"score_gpt":0.4967239650883408,"score_spread":0.4132586001346396,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}